Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the clinical efficacy of Ruxolitinib cream for skin conditions, reporting significant improvements in atopic dermatitis and vitiligo, with minimal systemic absorption and a favorable safety profile, compared to placebo.

This study found that MK-5108 is well tolerated at high doses as monotherapy in cancer patients, showing stable disease and some antitumor activity, particularly in combination with docetaxel.

This study found that TPA was significantly more effective than mezerein in inducing dark basal keratinocytes in mouse skin, which may be important in early tumor promotion stages.

This study described the safety profile of tyrosine kinase inhibitors in treating various solid tumors, finding that the observed toxicities were consistent with existing literature.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

This study found that tofacitinib may be effective for treating pediatric rheumatic diseases, with especially promising results in patients with autoinflammatory diseases, arthritis and alopecia, and juvenile dermatomyositis.

The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.

This article reviews the JAK signaling pathway and the development of ruxolitinib cream as a targeted treatment for inflammatory skin diseases, reporting no new clinical results.

This study found that coadministration of tadalafil and finasteride improved lower urinary tract symptoms and erectile function in men with benign prostatic hyperplasia better than finasteride alone over 26 weeks.

This study identified Azithromycin and Roxithromycin as novel senolytic antibiotics that effectively target and reduce senescent human fibroblast cells.

This review discusses testosterone replacement therapy, highlighting that most studies report no increased myocardial infarction risk when the therapy is properly administered with controlled hormone levels; it calls for careful consideration despite insurance coverage challenges.

This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.

This study found that a transdermal delivery system using 3% azone and P407 gel may enhance the skin permeation of doxazosin and finasteride for treating benign prostatic hyperplasia.

This review discusses the discovery and potential therapeutic uses of proteasome inhibitors across various diseases, including cancer and autoimmune conditions, but does not present new clinical data.

This report discusses Titanflow as a potential improvement in male urinary health by focusing on the detrusor muscle rather than prostate size, suggesting it may offer relief where other supplements have limited effectiveness.

This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

Both terazosin and baclofen effectively reduce pain in young men with chronic testicular pain, with no difference in their effectiveness.

This study reported that high-dose mizoribin therapy may be effective and safe for managing steroid-dependent pediatric systemic lupus erythematosus but requires monitoring of serum uric acid levels due to potential side effects.

This study observed that conjugates of the anticancer drug raltitrexed with dextran and albumin were more cytotoxic than the free drug at high concentrations, altering cell cycle effects.

In this study using a mouse model, the authors reported that the synthetic antioxidant TS-13 effectively inhibited tumor growth comparably to doxorubicin and reduced chemotherapy side effects, such as weight loss, splenotoxicity, and alopecia, more effectively when combined with the cytostatic treatment.

This review examines the role of topoisomerase-interacting drugs in cancer treatment and emphasizes the importance of understanding their mechanisms for clinical development, but it presents no new results.

This review discusses managing common and notable adverse events associated with the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-positive unresectable/metastatic breast cancer and reports no new clinical results.

This study found that formulating raloxifene in nano-lipid carriers significantly enhanced its permeation and cytotoxicity against cancer cells compared to raw raloxifene.

This review discusses the developments over the past five years in nanozyme-based theranostics for tumor therapy, including their classification, design, and synergistic strategies. It also outlines the challenges and prospects of using nanozymes to enhance selectivity, biosafety, repeatability, and stability in therapeutic applications.

This source describes Protetox as a natural dietary supplement that aids in weight loss by detoxifying the body, utilizing a blend of plant-based ingredients and antioxidants, and claims users have reported significant weight loss without changing their diet or exercise routines.

This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.

This study found that the combination of letrozole and quercetin loaded in spanlastics showed enhanced cytotoxicity and other anticancer effects against MCF-7 breast cancer cells compared to individual treatments.

In this case report, a 26-year-old man with alopecia universalis, resistant to multiple standard treatments, achieved complete and sustained hair regrowth with ruxolitinib, highlighting its potential as a promising option for patients with refractory AU.

This study developed cilostazol-loaded formulations for nose-to-brain delivery, finding that these formulations improved cilostazol's bioavailability by enhancing solubility, absorption, and permeability, achieving nearly 100% drug release in vitro within 2 hours.